Investment analysis, share recommendations, and market insights.
Here are three companies in the thriving (though small) sector of the ASX biotech world that are working to get to the heart of cardiac health. All three have unique approaches to it.
Raymond Chan, Private Adviser & Head of Asian Desk at Morgans, explains why Morgans considers REA a BUY.
Following interim reporting, ANZ Bank, National Australia Bank and Westpac feature prominently with three, two and one upgrades, respectively.
Here are four ETF ideas for conservative yield-focused investors as the cash rate rises.
Michael Gable, Managing Director of Fairmont Equities, shares his view with you on Macquarie Group (MQG).
In this week’s Boom Doom Zoom, we get a question on how to get in on the SpaceX IPO, and cover everything from Tabcorp to Telstra.
Is it time to relook at the healthcare sector? Here are 5 healthcare stocks that could be on the way up. But if you don't want to 'bet' on one company, possibly an ETF like the well-named DRUG, could be an option.
In a month where the US S&P 500 added 10.5%, the Aussie share market clawed higher in April to record a gain of just 2.2%. Our model portfolios, which are marginally overweight resources, continued to outperform.
Raymond Chan, Private Adviser & Head of Asian Desk at Morgans, explains why Morgans regards ResMed (RMD) as a BUY.
Here are three stocks, two with world-leading proprietary software and one with a growing specialisation in providing its clients with the capability and capacity to make AI viable for them. Each one looks to have substantial scope to rise from current prices.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.